<DOC>
	<DOCNO>NCT00002825</DOCNO>
	<brief_summary>Phase II trial study effectiveness docetaxel treat child recurrent solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Docetaxel Treating Children With Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate docetaxel child recurrent sarcoma , neuroblastomas , brain tumor . II . Describe toxic effect docetaxel patient . OUTLINE : All patient receive docetaxel G-CSF every 21 day 12 course . Patients follow survival .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically verify ( original diagnosis ) solid tumor relapse refractory The following histology eligible : Sarcomas : Rhabdomyosarcoma Ewing 's sarcoma , Peripheral neuroectodermal tumor ( PNET ) , Osteosarcoma , Other soft tissue sarcoma Brain tumor : Ependymoma Primitive neuroectodermal tumor ( PNET ) , High grade astrocytoma , Brain stem glioma ( histologic verification require ) , Neuroblastoma Measurable disease follow clinically radiologically require The following consider measurable : Bone lesion measure bone scan bone marrow involvement Central nervous system disease document cerebrospinal fluid cytology Pleural effusion PATIENT CHARACTERISTICS : Age : 21 original diagnosis Performance status : 03 Life expectancy : Greater 2 month In absence marrow involvement : Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 ( transfusion independent ) Hemoglobin least 9.0 g/dL ( transfusion allow ) With bone marrow involvement : Absolute neutrophil count least 750/mm3 Red cell platelet support possible Bilirubin normal ALT/AST le 1.5 time normal Alkaline phosphatase less 2.5 time normal Creatinine great 1.5 time normal OR creatinine clearance radioisotope glomerular filtration rate least 60 mL/min Not pregnant nursing Adequate contraception require fertile woman PRIOR CONCURRENT THERAPY : Prior bone marrow transplantation allow : Must stable engraftment without need significant blood product support cytokine therapy No concurrent immunomodulating agent No prior paclitaxel docetaxel At least 2 week since chemotherapy ( 4 week since nitrosoureas ) No concurrent cancer chemotherapy Concurrent corticosteroid allow intracranial pressure brain tumor patient provide patient stable least 4 week Corticosteroids allow pretreatment docetaxel At least 2 month since extensive radiotherapy , define : Craniospinal Volume great 50 % abdominopelvic cavity Volume great one third lung volume No concurrent radiotherapy No 2 prior therapy fully recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
</DOC>